95 related articles for article (PubMed ID: 20823413)
1. Small tumors, intermediate models, big hopes.
Siu LL
J Clin Oncol; 2010 Oct; 28(29):4407-9. PubMed ID: 20823413
[No Abstract] [Full Text] [Related]
2. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Chiu CW; Nozawa H; Hanahan D
J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
[TBL] [Abstract][Full Text] [Related]
3. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
Escudier B
J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
[No Abstract] [Full Text] [Related]
4. Phase I studies of drug combinations.
Verweij J; Disis ML; Cannistra SA
J Clin Oncol; 2010 Oct; 28(30):4545-6. PubMed ID: 20855831
[No Abstract] [Full Text] [Related]
5. A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?
Rhim AD
Cancer Biol Ther; 2009 Oct; 8(20):1902-3. PubMed ID: 19783905
[No Abstract] [Full Text] [Related]
6. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
Shepherd FA; Tsao MS
J Clin Oncol; 2006 Mar; 24(7):1219-20; author reply 1220-1. PubMed ID: 16505443
[No Abstract] [Full Text] [Related]
7. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatment combinations: integrating therapy into clinical practice.
Wong ST
Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S9-S14. PubMed ID: 19923318
[TBL] [Abstract][Full Text] [Related]
9. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
10. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Huang Z; Wu Y; Zhou X; Qian J; Zhu W; Shu Y; Liu P
Future Oncol; 2015; 11(11):1687-99. PubMed ID: 26043220
[TBL] [Abstract][Full Text] [Related]
12. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
13. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
14. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity.
Sharp ZD; Strong R
J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):580-9. PubMed ID: 20083554
[No Abstract] [Full Text] [Related]
15. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Cappuzzo F
J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643
[No Abstract] [Full Text] [Related]
16. Perspectives in central nervous system malignancies.
Stummer W
IDrugs; 2006 Jun; 9(6):412-4. PubMed ID: 16752310
[No Abstract] [Full Text] [Related]
17. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
18. [Molecular targeted therapy for malignant brain tumors].
Okamura T; Kurisu K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
[No Abstract] [Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
20. Update on novel therapies for pancreatic neuroendocrine tumors: 2013.
Dimou A; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):377-80. PubMed ID: 23846931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
